| Type 2 Diabetes Mellitus |
1 |
1 |
| Hypertension |
0 |
0.66 |
| Clinical Guidelines |
0 |
0.41 |
| Microbiome |
0 |
0.4 |
| Cerebrovascular Accident |
0 |
0.32 |
| Washington DC |
0 |
0.29 |
| Bacteria |
0 |
0.27 |
| Cardiovascular disease |
0 |
0.27 |
| Diet |
0 |
0.99 |
| Nutrition |
0 |
0.27 |
| Washington |
0 |
0.27 |
| Cardiovascular Risk Management |
0 |
0.16 |
| Obesity |
0 |
0.16 |
| Stem Cell Research and Therapy |
0 |
0.16 |
| Adverse Effects |
0 |
0.14 |
| Bladder |
0 |
0.14 |
| Bladder Cancer |
0 |
0.14 |
| Blood |
0 |
0.14 |
| Body Mass Index |
0 |
0.14 |
| Breast |
0 |
0.14 |
| California |
0 |
0.14 |
| Cancer |
0 |
0.14 |
| Clinical Research |
0 |
0.14 |
| Duodenum |
0 |
0.14 |
| Face |
0 |
0.14 |
| Food Contamination |
0 |
0.14 |
| Immunology |
0 |
0.14 |
| Indiana |
0 |
0.14 |
| Liver |
0 |
0.14 |
| Maryland |
0 |
0.14 |
| Meta-Analysis |
0 |
0.14 |
| Metabolism |
0 |
0.14 |
| Microbiology |
0 |
0.14 |
| Molecular Medicine |
0 |
0.14 |
| Noncommunicable Diseases |
0 |
0.14 |
| Pathogenesis |
0 |
0.14 |
| Salary and Compensation |
0 |
0.14 |
| Tolerance |
0 |
0.14 |
| Young Adult |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Patient Safety |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |